Search Results

You are looking at 21 - 30 of 746 items for :

  • "risk factors" x
  • Refine by Access: All x
Clear All
Full access

Jerome Kim and Arti Hurria

such as diabetes mellitus are associated with an increased risk of mortality in older adults with cancer, 27 , 28 whereas organ dysfunction such as renal insufficiency is a risk factor for chemotherapy toxicity. 7 , 8 Medications: Close to one

Full access

Darren R. Feldman, Wendy L. Schaffer, and Richard M. Steingart

. 15 – 18 For example, higher rates of digital ischemia were identified in patients treated with cisplatin compared with those who were not (41% vs. 21%). 14 The cumulative dose of chemotherapy and the prevalence of conventional risk factors for

Full access

James J. Harding, Ghaith Abu-Zeinah, Joanne F. Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E. Kemeny, Eileen M. O'Reilly, Leonard B. Saltz, and Ghassan K. Abou-Alfa

's test was used to compare the cumulative incidence functions by covariates of interest including age, sex, race, treatment era, HCC etiologic risk factor, Child-Pugh score, AFP level, and median calcium and ALP levels. Among patients who presented with

Full access

Craig H. Moskowitz, Andrew Zelenetz, and Heiko Schoder

stages II, III, or IV disease and 1 to 3 risk factors according to age-adjusted International Prognostic Index score. After induction therapy with 4 cycles of R-CHOP-14, all patients underwent FDG-PET. Patients who had negative FDG-PET results then

Full access

Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald, and Andrea B. McKee

(NLST) entry criteria. 1 – 4 All 3 organizations have expanded their screening recommendations to include older patients, younger patients, and/or patients with additional risk factors for lung cancer. Inclusion of these additional populations has

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

recurrence rates. In addition, the authors seek to analyze whether this effect varies by drug or by baseline patient risk factors. Methods Literature Search Strategy The authors searched the Cochrane Controlled Trials Register (CENTRAL

Full access

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

-intent resection of CLM, it is critical to explore this issue further and develop a potential surveillance algorithm specific to this patient cohort. Within this context, the primary aim of this study was to assess the changes in recurrence risks and risk factors

Full access

Ruben Niesvizky and Ashraf Z. Badros

preventing, identifying, and managing them. Venous Thromboembolism VTE typically manifests as deep vein thrombosis (DVT) or pulmonary embolism (PE). Both cancer and cancer treatments have been identified as discrete risk factors. 1 Current evidence

Full access

Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im, and Jung-Hwan Yoon

, 30 Patients with cirrhosis are more likely to develop hepatic decompensation, resulting in hepatic failure. 5 Risk Factors for HBV Reactivation: Patient Factors, Cancer Type, and Treatment Factors Identifying risk factors for HBV reactivation

Full access

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

study period (median follow-up, 15 months [IQR, 4 months to 4.2 years]); all were attributed to the patients’ malignancies. Patient Characteristics According to Esophagitis Risk Factors We compared the clinical characteristics of patients with risk